Although SGLT-2 inhibitors primarily aim to reduce hyperglycemia in patients with type 2 diabetes, they exert additional effects that may contribute to the observed reduction of CV events, hospitalization for HF, and overall mortality. This evidence concerns the gene SLC5A2 and hydrops fetalis.